Physician profile
Mark Leischner
NPI 1598708877
$1,437.10
in general payments reported to CMS, 2019-2025
17 companies · $314 in 2025
The $314 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $135 · 2021: $135 · 2022: $143 · 2023: $311 · 2024: $186 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $254.83 | 2023 | Abre, Ellipsys Vascular Access System |
| Fresenius USA Marketing, INC. | $210.93 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Horizon Therapeutics Plc | $151.47 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $103.53 | 2022 | |
| Akebia Therapeutics INC | $96.03 | 2021 | |
| Calliditas Therapeutics US INC. | $92.89 | 2024-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $85.75 | 2024-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.28 | 2023-2025 | Jardiance |
| Nxstage Medical, INC. | $79.29 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $61.20 | 2019 | |
| Amgen INC. | $56.84 | 2019 | |
| Aurinia Pharma U.S., INC. | $34.44 | 2025 | Lupkynis |
| Ardelyx, INC. | $34.16 | 2024 | Ibsrela |
| Lilly USA, LLC | $29.76 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $26.53 | 2023-2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $19.35 | 2025 | |
| Merck Sharp & Dohme LLC | $14.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Leischner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.